Identifies antimicrobial resistance in Streptococcus agalactiae, suggesting urgent genomic surveillance needs.
Streptococcus agalactiae poses a threat due to increasing antimicrobial resistance and the potential for invasive disease. We isolated a sequence type 1665 strain nonsusceptible to β-lactams and resistant to macrolides, tetracyclines, and fluoroquinolones, harboring previously uncharacterized PBP2X variants, highlighting the need for genomic surveillance to guide treatment and infection control.
No takes yet. Share an insight, caveat, or question.
Kanehira et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: